Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Vertex Pharmaceuticals Inc issues FY 2014 revenue guidance below analysts' estimates

Wednesday, 29 Jan 2014 04:01pm EST 

Vertex Pharmaceuticals Inc:Expects FY 2014 total revenue to be in the range of $570-$600 mln.FY 2014 revenue of $631 mln - Thomson Reuters I/B/E/S. 

Company Quote

-0.19 -2.51%
20 Aug 2014